Document Detail

Renal cancer biomarkers : What is justified?
MedLine Citation:
PMID:  23052348     Owner:  NLM     Status:  Publisher    
Renal carcinoma biomarkers are of potential interest for the diagnosis of renal tumor subtypes and prediction of prognosis or reponses to targeted therapies. Due to the identification of novel renal tumor subtypes, diagnostic immunohistochemical biomarkers are of increasing importance. However, there is currently not enough clinical evidence to recommend prognostic or predictive biomarkers in routine pathology. Therapeutic decisions are still based on correct tumor classification, tumor differentiation grade, and tumor stage. Recent studies have emphasized the relevance of detailed analysis of hilus fat tissue for a correct pT-category. This review summarizes recent developments in renal cancer biomarker research.
H Moch
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-10-11
Journal Detail:
Title:  Der Pathologe     Volume:  -     ISSN:  1432-1963     ISO Abbreviation:  Pathologe     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-10-11     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8006541     Medline TA:  Pathologe     Country:  -    
Other Details:
Languages:  GER     Pagination:  -     Citation Subset:  -    
Institut für Klinische Pathologie, UniversitätsSpital Zürich, Schmelzbergstr. 12, 8091, Zürich, Schweiz,
Vernacular Title:
Biomarker für Nierenkarzinome : Was ist gerechtfertigt?
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Hereditary gastric cancer.
Next Document:  Histopathology of microscopic colitis.